\
&
Contact us
This was 1 year ago
LocationRoyal Military Academy
The Belgian Royal Higher Institute for Defence and US Army DEVCOM and US Office of Naval Research – Global are inviting you to this second bilateral workshop on defence research. The aim of the event is to familiarize the Belgian Research community with available funding mechanisms and to identify and share new, crazy and potentially disruptive ideas (as opposed to discussing past successes).
The “Forging the future – BE-US joint effort in science for a safer world” workshop will be the second edition of this event introducing Belgian research and technology community to representatives from the Belgium Ministry of Defence (MoD) and the United States of America – Department of Defence (DoD). This meeting will provide academic institutions, research institutions, industries (big and small cap) and government representatives with the opportunity to discuss emerging research and technologies across a broad range of topic areas with the goal of building collaboration across the research community and with government agencies.
The workshop programme will be built around five topical areas where researchers will be presenting 10-minutes “lightning” talks describing their blue sky, crazy ideas.
Topic areas: quantum, biotechnologie, AI, autonomy, hypersonics material sciences.
This event will also offer the occasion for networking opportunities and the possibility of bilateral talks with BEL Defence and/or US Defence funding authorities.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.